Bifidobacterium longum longum & Irritable Bowel Syndrome (IBS)

Clinical data

• XXX - Bifidobacterium longum longum 35624 & Irritable Bowel Syndrome (IBS)

This randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial revealed that Bifidobacterium longum longum 35624 is a probiotic known for its effectiveness in alleviating many symptoms associated with Irritable Bowel Syndrome (IBS). Administered at a dosage of 1 × 10^8 colony-forming units (cfu), it is conveniently delivered in capsule form, ensuring stability and ease of use, which makes it suitable for widespread application.

The observed lack of benefits at other dosage levels underscores the importance of clinical data to determine the optimal dosage form and amount before these probiotic pro…